Dyadic International, Inc. (NASDAQ:DYAI – Get Free Report) saw a significant decline in short interest in the month of October. As of October 31st, there was short interest totalling 183,700 shares, a decline of 9.6% from the October 15th total of 203,300 shares. Based on an average daily trading volume, of 25,100 shares, the days-to-cover ratio is currently 7.3 days. Currently, 0.9% of the company’s shares are short sold.
Institutional Investors Weigh In On Dyadic International
Hedge funds and other institutional investors have recently bought and sold shares of the business. Charles Schwab Investment Management Inc. purchased a new stake in Dyadic International in the second quarter worth about $32,000. AE Wealth Management LLC purchased a new stake in shares of Dyadic International in the second quarter worth $35,000. Captrust Financial Advisors purchased a new stake in shares of Dyadic International in the first quarter worth $45,000. Atria Wealth Solutions Inc. purchased a new stake in shares of Dyadic International in the third quarter worth $46,000. Finally, Chapin Davis Inc. grew its stake in Dyadic International by 1.1% during the second quarter. Chapin Davis Inc. now owns 832,301 shares of the biotechnology company’s stock valued at $1,606,000 after acquiring an additional 9,000 shares in the last quarter. Hedge funds and other institutional investors own 15.58% of the company’s stock.
Analyst Upgrades and Downgrades
Separately, HC Wainwright reiterated a “buy” rating and set a $6.00 price target on shares of Dyadic International in a research report on Monday.
Dyadic International Price Performance
Shares of NASDAQ DYAI opened at $1.70 on Thursday. The stock has a market capitalization of $48.98 million, a P/E ratio of -7.39 and a beta of 0.62. Dyadic International has a 1 year low of $1.12 and a 1 year high of $2.40. The company’s 50-day moving average is $1.80 and its 200 day moving average is $1.90.
Dyadic International Company Profile
Dyadic International, Inc, a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. It utilizes its patented and proprietary C1 platform and other technologies to conduct research, development, and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus-like particles, protein antigens, ferritin nanoparticles, monoclonal antibodies, bi/tri-specific antibodies, fab antibody fragments, Fc-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins.
- Five stocks we like better than Dyadic International
- Stock Dividend Cuts Happen Are You Ready?
- 3 value stocks you shouldn’t let go of this quarter
- What is MarketRank™? How to Use it
- 5 must-have next-gen technologies that institutions are buying
- How to Invest in Blue Chip Stocks
- 3 intriguing late-week earnings plays for short-term traders
Receive News & Ratings for Dyadic International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dyadic International and related companies with MarketBeat.com's FREE daily email newsletter.